| Autor: |
Mukherjee, S, Virdee, P, Shaw, R, Bridgewater, J, Radhakrishna, G, Falk, S, Scott-Brown, M, Strauss, V, Brookes, C, Gillmore, R, Patel, N, Tranter, B, Parsons, P, Sebag-Montefiore, S, Hawkins, M, Corrie, P, Maughan, T |
| Rok vydání: |
2018 |
| Popis: |
The anti-retroviral agent, nelfinavir, demonstrates radiosensitising effects in pre-clinical models of pancreatic cancer. The primary objective of Stage 1 was to establish the maximum tolerated dose (MTD) of nelfinavir combined with capecitabine-chemoradiation (CRT) after gemcitabine+nab-paclitaxel (GEMABX) induction chemotherapy. Other outcomes included overall survival and progression-free survival. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
